| Identification | Back Directory | [Name]
NSC 42834 | [CAS]
195371-52-9 | [Synonyms]
NSC 42834
1-Butanone
NSC 42834，Z3
Z3(NSC 42834)
JAK2 Inhibitor V
NSC 42834,Z3, >95%
JAK2 Inhibitor V, Z3
JAK2 Inhibitor V, Z3, >=98%
NSC 42834 (JAK2 INHIBITOR V)
NSC 42834(JAK2 Inhibitor V, Z3)
2-methyl-1-phenyl-4-(2-pyridinyl)-2-[2-(2-pyridinyl)ethyl]-
2-Methyl-1-phenyl-4-(2-pyridinyl)-2-[2-(2-pyridinyl)ethyl]-1-butanone
1-Butanone, 2-Methyl-1-phenyl-4-(2-pyridinyl)-2-[2-(2-pyridinyl)ethyl]-
2-METHYL-1-PHENYL-4-(PYRIDIN-2-YL)-2-(2-(PYRIDIN-2-YL)ETHYL)BUTAN-1-ONE
Z3;NSC 42834;1-BUTANONE; 2-METHYL-1-PHENYL-4-(2-PYRIDINYL)-2-[2-(2-PYRIDINYL)ETHYL]-
NSC 42834 2-Methyl-1-phenyl-4-(2-pyridinyl)-2-[2-(2-pyridinyl)ethyl]-1-butanone
NSC 42834 Z 3 2-Methyl-1-phenyl-4-(2-pyridinyl)-2-[2-(2-pyridinyl)ethyl]-1-butanone | [Molecular Formula]
C23H24N2O | [MDL Number]
MFCD00023550 | [MOL File]
195371-52-9.mol | [Molecular Weight]
344.45 |
| Chemical Properties | Back Directory | [Boiling point ]
520.4±50.0 °C(Predicted) | [density ]
1.106±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 30 mg/ml; DMSO: 20 mg/ml; Ethanol: 30 mg/ml; Ethanol:PBS(pH 7.2) (1:1): 0.5 mg/ml | [form ]
Powder | [pka]
5.90±0.12(Predicted) | [color ]
Colorless to light yellow |
| Hazard Information | Back Directory | [Uses]
NSC 42834 (JAK2 Inhibitor V), a novel specific inhibitor of Jak2, inhibits Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity. | [IC 50]
JAK2-WT: 15 μM (IC50); JAK2-V617F: 28 μM (IC50) | [References]
[1] Jacqueline Sayyah, Andrew Magis, David A. Ostrov, et al. Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth . Mol Cancer Ther 2008;7(8):2308-18.
[2] Jacqueline Sayyah, Peter P. Sayeski. Jak2 inhibitors: Rationale and role as therapeutic agents in hematologic malignancies. Current Oncology Reports. 2009, 11(2): 117-124.
[3] Ehab Atallah , Srdan Verstovsek . Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. Expert Review of Anticancer Therapy. 2009,9 (5):663-670. |
|
|